Home
Storia in 2 fonti
AstraZeneca follows Merck with Phase 3 win in bladder cancer
A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday.
- ·
endpoints.news
AstraZeneca follows Merck with Phase 3 win in bladder cancer
A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday.
- ·
fiercepharma.com
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval in muscle-invasive bladder cancer patients who are…